DIRS.INFO The most relevant business & tech news

☆ Novo Nordisk asks FDA to ban compounding pharmacies from making Ozempic, Wegovy copies
▼ + stars: | 2024-10-23 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

Boxes of Ozempic and Wegovy made by Novo Nordisk are seen at a pharmacy. The FDA still has to make a final decision on whether to bar compounded versions of semaglutide, the active ingredient in Ozempic and Wegovy. In a statement, the agency said it is reviewing the petition and will respond directly to Novo Nordisk. The active ingredient in Wegovy and Ozempic, semaglutide, has been in intermittent shortages over the past two years. Like Novo Nordisk, Eli Lilly has sued several weight loss clinics, medical spas and compounding pharmacies across the U.S. over the past year.

Persons: Wegovy, Danish drugmaker, semaglutide, Eli Lilly, Eli Lilly's, compounders Organizations: Novo Nordisk, Tuesday, Food and Drug Administration, FDA, Nordisk Locations: Novo, Danish, U.S

☆ U.S. FDA to reconsider decision barring compounded versions of Lilly weight loss drug
▼ + stars: | 2024-10-12 | by ( ) www.cnbc.com time to read: +1 min

The U.S. Food and Drug Administration on Friday agreed to reconsider a decision it made last month to bar drug compounders from selling their own versions of Eli Lilly's blockbuster weight loss and diabetes drugs. The compounding versions of the drugs are cheaper for patients than the brand-name versions. The Sept. 30 decision by the FDA endangered the ability of compounders to sell versions of Lilly's weight loss drug Zepbound and diabetes drug Mounjaro. The FDA decision removed their active ingredient, tirzepatide, from its list of drugs experiencing shortages. Insurers generally cover drugs like tirzepatide for diabetes, but many do not cover them for weight loss.

Persons: Eli Lilly's, Mark Pittman Organizations: . Food, Drug Administration, Outsourcing, Association, District, FDA Locations: U.S, Fort Worth , Texas

☆ These are the most important stocks in the U.S., according to Bank of America
▼ + stars: | 2024-10-04 | by ( Pia Singh | In | ) www.cnbc.com time to read: +3 min

There are several key stocks in the U.S. investors need to be mindful of when navigating the current market environment, according to Bank of America. To capture the momentum from this rally, Bank of America screened for the most important stocks in each region of the world — including the U.S. — that have the potential to have the largest impact on portfolio performance, positive or negative. Bank of America found these stocks to be among the most important in the U.S.: Chipmaker Nvidia and oil and gas giant Exxon Mobil ranked fairly high on the firm's steady compounders list within the screen. Meta's shares are up nearly 64% year to date. Other stocks considered the most important names in the U.S. include rideshare company Uber and pharma name Eli Lilly .

Persons: Nigel Tupper, Vivek Arya's, Metaverse, Justin Post, Eli Lilly Organizations: Bank of America, Investment, U.S, Nvidia, Exxon Mobil, Exxon, Meta, Bank of America's, Uber Locations: U.S, Lebanon, Thursday's

☆ 10 things to watch in the market Thursday, including great news from Nvidia's CEO
▼ + stars: | 2024-10-03 | by ( Jeff Marks | ) www.cnbc.com time to read: +7 min

My top 10 things to watch Thursday, Oct. 3 Today's newsletter was written by the Investing Club's director of portfolio analysis, Jeff Marks. But the analysts said they would be buyers of the Club stock on weakness in 2025. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. My top 10 things to watch Thursday, Oct. 3Today's newsletter was written by the Investing Club's director of portfolio analysis, Jeff Marks. But the analysts said they would be buyers of the Club stock on weakness in 2025.

Persons: Jeff Marks, Stocks, Dow, Beer, Jensen Huang, Blackwell, Eli Lilly, Morgan Stanley, Oppenheimer, Levi Strauss, Levi, Jim Cramer's, Jim Cramer, Jim Organizations: Nasdaq, Constellation Brands, Modelo, Corona, Constellation, Nvidia, CNBC, Club, Bank of America, Devices, Amazon, Deutsche Bank, Costco, Dockers, Barclays, PepsiCo, Jim Cramer's Charitable Locations: Northern New Jersey, Europe, Americas

☆ Weight-loss drugs are life-changing — and expensive. Here's one woman's solution.
▼ + stars: | 2024-09-26 | by ( ) www.businessinsider.com time to read: +7 min

A woman who had life-changing results on a popular weight loss drug struggled to afford it for years. AdvertisementTara Rothenhoefer, a 49-year-old Florida resident, says her life changed when she joined a clinical trial for a promising new weight-loss medication. While regulated, these compounded drugs aren't FDA-approved, raising concerns from doctors about variations in quality. The grey market of weight-loss drugs is vast and complicated. In August, Eli Lilly halved the price of its weight-loss drug Zepbound through single-dose vials — a bid to lure customers back to brand-name drugs, analysts said.

Persons: —, Tara Rothenhoefer, Rothenhoefer, Eli Lilly, She's Organizations: Service, Novo Nordisk's, Research, FDA, Pharmaceutical Locations: Florida

☆ Nearly half of online pharmacies selling weight loss drugs are operating illegally, study finds
▼ + stars: | 2024-08-02 | by ( Liz Szabo | Liz Szabo Is An Independent Health | Science Journalist. Her Work Has Won Multiple National Awards. One Of Her Investigations Led To A New State Law In Virginia. | ) www.nbcnews.com time to read: +8 min

Consumers who try to buy popular weight loss drugs online without a prescription risk being scammed or receiving unsafe products, a new study shows. Shortages of the popular weight loss medication, which belongs to a class of drugs called GLP-1s, have led to “a black market of illegal knockoffs,” said Dr. Christopher McGowan, the founder, medical director and research director of True You Weight Loss, a weight loss clinic in Cary, North Carolina. Medicare doesn’t cover the drugs when prescribed for weight loss, and many state Medicaid plans heavily restrict coverage. Online scamsSome websites purporting to be online pharmacies take consumers’ money but never deliver the medications, according to the study. Consumers won’t get that sort of care if they buy drugs online without seeing a health care provider.

Persons: ”, Tim Mackey, Christopher McGowan, McGowan, semaglutide, won’t, Mackey, ” McGowan, “, Shabbir Safdar, Scott Brunner, Safdar, Brunner, Consumers won’t, it’s Organizations: Nordisk’s, University of California, Global Health, Data Institute, University of Pecs, FDA, Manufacturers can’t, Medicare, JAMA, Food and Drug Administration, semaglutide, Novo Nordisk, telltale, Partnership, Safe Medicines, Alliance, Pharmacy, Consumers Locations: San Diego, Hungary, Cary , North Carolina, U.S

☆ This software stock is quietly one of the best tech stocks of the decade and Bank of America sees more gains ahead
▼ + stars: | 2024-05-30 | by ( Pia Singh | ) www.cnbc.com time to read: +2 min

Cadence Design Systems is well ahead of its artificial intelligence peers when it comes to delivering steady returns, according to Bank of America. The electronic systems design company is a "high-quality growth compounder" that's "well levered to AI," analyst Vivek Arya said in a Wednesday note to clients. Cadence develops software, hardware and intellectual property that is used to design chips and printed circuit boards, among other related products. "Over the past decade CDNS has delivered 33% annualized returns, 300bps ahead of rival SNPS , and among top 5 across our coverage, well-ahead of SOX index up 25%. Importantly, CDNS stock has outperformed the SOX index each of the 18 times the SOX index declined by over 10% since 2010."

Persons: Vivek Arya, Arya, CDNS Organizations: Cadence Design Systems, Bank of America, Cadence, PHLX Semiconductor, SOX, Nvidia, AMD, Samsung Locations: SOX

☆ Deutsche Bank says it's time to invest in trash through these 2 stocks: 'Compounding defensive growth'
▼ + stars: | 2024-05-22 | by ( Pia Singh | ) www.cnbc.com time to read: +3 min

Alwy initiated coverage of Waste Management and Waste Connections with a buy rating on each. His $241 price target on Waste Management suggests 15.7% upside, and his $189 price target on Waste Connections implies the stock has roughly 14.4% to rise. This year, Waste Management shares are up 17.2%, while Waste Connections has added 11%. Waste Connections is planning to invest $150 million, most of which will be used for renewable natural gas, or RNG, projects, she said. With that price target, she expects shares could add 7.3%.

Persons: Alwy Organizations: Deutsche Bank, Waste Management, Waste, Services, Casella Waste Systems Locations: American, North America

☆ These 5 stocks are perfect examples of a time-tested strategy that can outperform in any market, according to a stock-picker whose ETF beat 90% of its peers in its first full year
▼ + stars: | 2024-04-30 | by ( James Faris | ) www.businessinsider.com time to read: +4 min

The Copenhagen-based firm subadvises funds like the Harbor International Compounders ETF (OSEA), which O'Reilly has co-managed since its launch in early September 2022. But despite launching less than two years ago, O'Reilly said in a recent interview that the ETF's success didn't happen overnight. "We feel the strategy that we have can work in any market environment," O'Reilly said. The ETF is more balanced when it comes to countries, as no more than 13% of its stocks are from a single nation. 5 international stocks to buy nowAfter outlining his investing strategy, O'Reilly spoke about five companies he's especially excited about now.

Persons: Peter O'Reilly, who's, O'Reilly, You've, he's, Germany — Organizations: London, Asset Management, Business, Carnegie Asset Management Locations: Ireland, Dublin, Copenhagen, France, Japan, United Kingdom, Germany

☆ These 'all-weather stocks' can thrive in any economy and provide strong long-term returns, according to UBS
▼ + stars: | 2024-04-10 | by ( Brian Evans | ) www.cnbc.com time to read: +3 min

As inflation concerns remain at the forefront of investors' minds, UBS is eyeing stocks that can find growth no matter the economic cycle. "We define compounders as all-weather stocks that leverage operational excellence and competitive advantages to grow through any phase of the economic cycle," analyst Joseph Parkhill wrote on Tuesday. S & P 500 stocks are trading near all-time high valuations of 20 times price to earnings and 14 times enterprise value/EBITDA, Parkhill said. Here's a look at some of the 17 stocks that UBS is watching. Stocks also on the UBS list include artificial intelligence plays Microsoft and Broadcom .

Persons: Joseph Parkhill, Parkhill, AMZN, Stephen Ju, Jay Sole, Stocks Organizations: UBS, Amazon, Microsoft, Broadcom

☆ Comeback candidates: Goldman loves these underperforming stocks with strong fundamentals
▼ + stars: | 2024-04-10 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +3 min

Stocks that have missed out on this year's market rally could be solid contenders for a rebound, according to Goldman Sachs. Heading into the second quarter, Goldman searched for buy-rated names in its coverage universe that could win big going forward. Goldman screened for "compounders," which offer investors high financial returns, free cash flow generation, margin expansion and sales growth. Most analysts covering the stock currently have a buy rating assigned to the name, with about 39% upside to the consensus price target, per LSEG. Pfizer stock has slipped 9% this year.

Persons: Goldman Sachs, Goldman, Dan Levy, Levy, Guggenheim, Vamil Divan, Lamb Weston, Jefferies, Rob Dickerson Organizations: Barclays, Pfizer Locations: U.S

☆ The 11 GRANOLAS stocks power Europe to record highs, drawing Magnificent Seven comparisons
▼ + stars: | 2024-02-27 | by ( Elliot Smith | ) www.cnbc.com time to read: +3 min

The German share price index DAX graph is pictured at the stock exchange in Frankfurt, Germany, January 19, 2024. Staff | ReutersOver the last 12 months, just 11 stocks made up half of the gains that powered the pan-European Stoxx 600 stock index to a record-high close on Friday. "From a Global point of view, the GRANOLAS have even outperformed the so-called Magnificent 7 over the past two years. Their (out)performance is even more impressive on a risk-adjusted basis: with a volatility 2x lower than for the Magnificent 7, the GRANOLAS help to boost the Sharpe ratio." "This suggests that, in Europe, nearly all revenue growth of the STOXX 600 will come from the GRANOLAS.

Persons: Goldman Sachs, Sanofi —, Goldman, Tim Hayes, Ned Davis, Hayes Organizations: Staff, Reuters, GSK, Roche, ASML, Nestle, Novartis, Novo Nordisk, L'Oreal, LVMH, AstraZeneca, SAP, Sanofi, Street, Ned, Ned Davis Research, CNBC Locations: Frankfurt, Germany, Europe

☆ Here are Wednesday's biggest analyst calls: Tesla, Nvidia, Arm, Citi, Walmart, First Solar, Ulta, GE & more
▼ + stars: | 2024-02-14 | by ( Michael Bloom | ) www.cnbc.com time to read: +7 min

UBS downgrades Waste Management to neutral from buy UBS said the trash company has a "lofty" valuation. Citi reiterates Nvidia as buy Citi said its standing by its buy rating heading into earnings next week. " UBS upgrades HF Sinclair to buy from neutral UBS said the refiner is underappreciated. UBS upgrades Huntington Bancshares to buy from neutral UBS said it sees "strong strategic positioning" for the regional bank. Citi downgrades GlobalFoundries to neutral from buy Citi downgraded the semi company following earnings on Tuesday.

Persons: Wells, Redburn, Morgan Stanley, Tesla, it's, Piper Sandler, Piper, Jane Fraser's, Q, BRKRs, BRKR, DINO, D.A, Davidson downgrades Airbnb, Evercore, GlobalFoundries, Bernstein, Wingstop Organizations: Wells, RBC, Enphase Energy, Shoals Technologies, SolarEdge Technologies, UBS downgrades Waste Management, UBS, Citi, Nvidia, JPMorgan, Sinclair, diesel, Deutsche Bank, General, Deutsche, GE, ABNB, ABNB's, Walmart, ISI, Huntington, HSBC, Palantir, HP, Bank of America, of America, Design Systems, Rivals Locations: EBITDA

☆ Ro, the $7 billion healthcare startup, has a high-stakes strategy to take off-brand Ozempic mainstream
▼ + stars: | 2024-02-07 | by ( ) www.businessinsider.com time to read: +11 min

The $7 billion healthcare startup Ro, which has been prescribing brand-name weight-loss shots since January 2023, now offers compounded semaglutide to patients enrolled in its weight-management program. Nonetheless, Ro is the first prominent healthcare company to effectively endorse compounded semaglutide by prescribing it. A poor-quality compounded drug might simply be a dud and a waste of money. But while compounding pharmacies are subject to FDA and state regulations, states are the main regulators, and their oversight is patchy. Michael Siluk/UCG/Universal Images Group via Getty ImagesIt's hard to know if any given vial of compounded semaglutide is safe.

Persons: Wegovy's, Ro, drugmakers, Eli Lilly's, Eli Lilly's Mounjaro, Scott Gottlieb, Michael Siluk, That's, they've, Ozempic, Eli Lilly, Eric Kastango, they're, Kastango, aren't, Al Carter, Sarah Jones Simmer, Spencer Nadolsky, WeightWatchers, Tim Church, Wondr, it's, hasn't Organizations: Business, Novo Nordisk's Wegovy, US Food and Drug Administration, FDA, Novo Nordisk's Ozempic, Getty, Novo Nordisk, USP, National Association of, Pharmacy, Health Locations: Novo, Massachusetts, Austria, New York City

☆ Goldman Sachs is pounding the table for these top tech stocks ahead of earnings
▼ + stars: | 2024-01-27 | by ( Michael Bloom | ) www.cnbc.com time to read: +5 min

Goldman Sachs is getting bullish on tech ahead of key earnings. CNBC Pro combed through Goldman Sachs research to find the firm's favorite tech names as earnings season heats up. Microsoft Analyst Kash Rangan expects big results from Microsoft when the company issues its fiscal second-quarter report on Tuesday . Broadcom Goldman recently reinstated coverage of the semiconductor company with a buy rating ahead of its earnings report in February. In addition, the VMware deal should "drive operating margin expansion and earnings growth well in excess of the industry average," he said.

Persons: Goldman Sachs, Kash Rangan, Rangan, Broadcom Goldman, Toshiya Hari, Hari, Apple Goldman, Michael Ng, Ng, … AAPL Organizations: CNBC, Apple, Microsoft, Broadcom, VMware, Apple Services, Apple Music, Apple Vision, Semiconductor, TAM Locations: CY23

☆ Wall Street says buy these 2 industrial-focused stocks. Here’s our view on each
▼ + stars: | 2023-12-11 | by ( Morgan Chittum | ) www.cnbc.com time to read: +6 min

Wall Street analysts are saying it's a great time to invest in two of our favorite industrial-focused stocks: Honeywell and Linde . Morgan Stanley on Monday raised its price target and kept its buy-equivalent rating on industrial gas and engineering firm Linde. As for Linde, Jim has long touted the stock as the Club's favorite way to invest in the global transition to clean energy. On Dec 1, we increased our Club price target on Linde to $440 per share from $410. The Club's price target is $225, reflecting about a 12.5% premium to where the stock traded Monday afternoon.

Persons: Morgan Stanley, Linde, Jim Cramer, he's, Jim, Vimal Kapur, It's, Kapur, Jim Cramer's Organizations: Honeywell, Linde, Bank of America, LIN, Biden, of America, Carrier, CNBC, Getty

Uber shares rose 5% in extended trading on Friday after the ride-hailing company was added to the S&P 500 Index, replacing Sealed Air Corp. A company's stock price often rises on news that it's joining the S&P 500 because fund managers who track the benchmark, which gets updated each quarter, have to acquire the shares. Uber shares debuted on the New York Stock Exchange in 2019, but the company was burning cash as it had to pay drivers enough money to stay competitive in a low-margin business. Uber has a market cap of about $118 billion, while the median market cap of companies in the S&P 500 is just over $31 billion. WATCH: Uber into the S&P 500

Persons: Dara Khosrowshahi, it's, Nelson, Chai, Uber, Lloyd Walmsley, You've Organizations: Uber, Sealed Air Corp, Companies, New York Stock Exchange, UBS Locations: Davos, Switzerland

☆ The manager of the top-performing small-cap fund this year outlined his 4 criteria for finding strong investments — and revealed his 3 favorite hidden gem stock picks right now
▼ + stars: | 2023-11-21 | by ( Mark Reeth | ) www.businessinsider.com time to read: +8 min

With a name like the Needham Aggressive Growth Fund, you'd be forgiven for assuming portfolio manager John Barr hunts for growth at any cost. So yes, it's growth investing informed by value investing." The Needham Aggressive Growth Fund has returned over 25% year-to-date according to Morningstar, making it the best-performing small-cap fund on the market. Barr, a one-time software salesman turned investing pro, told Business Insider what he looks for in his investments, the market themes he's watching, and his favorite stock picks right now. But it's Barr's primary investment criteria that sets him apart from other growth-focused fund managers: finding "hidden-to-quality compounders."

Persons: you'd, John Barr, Barr, that's, Charlie Munger, Warren Buffett, Morningstar, I've, there's, —, they've Organizations: Berkshire Hathaway, Business, Fund, Micro, Google, Vishay, Vishay Group, Parsons Corporation, Missile Defense Agency, Department of Defense

☆ Morgan Stanley says these 3 global stocks will be 'winners' in a world where data is king
▼ + stars: | 2023-10-12 | by ( Amala Balakrishner | ) www.cnbc.com time to read: +3 min

The analysts see Relx and Wolters Kluwer benefiting from "clear opportunities" from generative artificial intelligence. Relx and Wolters Kluwer The bank raised its forecasts for Relx and Wolters Kluwer, giving both an overweight rating. Its price target for Wolters Kluwer is 142 euros ($150.59), or around 18% upside. They like Wolters Kluwer for its software business, which generates around 45% of its revenue. Morgan Stanley has a price target of £790 on the company – giving it an 8.5% upside from its Oct. 10 close.

Persons: Morgan Stanley, George Webb, Wolters, Relx, Morgan, — CNBC's Michael Bloom Organizations: Wolters Kluwer, Relx, Nasdaq, REL, Relx's, LexisNexis Locations: Europe, WKL

☆ How this aggressive growth fund beat the S&P 500 without Nvidia or Big Tech
▼ + stars: | 2023-09-11 | by ( Weizhen Tan | ) www.cnbc.com time to read: +4 min

Many growth funds have performed on pace with the S & P 500 this year, driven by mega-cap names such as Nvidia , Alphabet and Tesla . The Needham Aggressive Growth Fund , however, has outperformed. Aggressive growth funds are focused on investing in growth stocks, with high potential future to grow — but also higher risk. Picking companies Portfolio manager Barr, who has managed the fund since 2010, told CNBC Pro that "there is a rich universe of investment opportunities beneath the big tech companies like Nvidia." "There are small-cap companies with rapid growth, and also with the steady growth that Needham prefers."

Persons: It's, John Barr —, Barr, Needham Organizations: Nvidia, Big Tech, Morningstar, CNBC, Apple, Needham Funds Locations: industrials, Barr, United States

☆ A top-7% fund manager over the past 15 years shares the once-in-a-generation challenge she sees in markets — and names 6 stocks that look attractive right now
▼ + stars: | 2023-09-02 | by ( James Faris | ) www.businessinsider.com time to read: +3 min

The mid-cap growth fund manager shared what qualities she's looking for in stocks. However, the mid-cap growth fund she's managed since 2001 is still a top-7% performer in the last 15 years, according to Morningstar. There's 'magic' to be found in mid-cap growthBut while elevated interest rates aren't kind to stocks, Scott still sees opportunities in many mid-sized companies. Within mid caps, Scott tends to tilt toward growth-focused companies, specifically those with sound business models that are profitable and have abundant cash flow. Instead of investing in so-called "bleeding edge" growth stocks, Scott said she prefers steady, reliable compounders.

Persons: Kimberly Scott, she's, we've, Scott, Morningstar, we're Organizations: Delaware Ivy, Growth, Federal, Growth Fund

☆ Goldman loves this 'cash flow compounder' and predicts nearly 30% upside
▼ + stars: | 2023-08-14 | by ( Pia Singh | ) www.cnbc.com time to read: +2 min

"TDY is one of the highest quality, most consistent, best managed companies we cover that compounds cash flow over time," analyst Noah Poponak said. Cash flow compounders reinvest their excess free cash flow each year back into the company at a rate that is sustainable and provide long-term growth. Teledyne has compounded free cash flow at a 17% compound annual growth rate over the last decade, according to the Goldman note. According to Poponak, Teledyne's margins have expanded over time by shifting into higher value-added business lines, which he expects will support continued EPS and free cash flow compounding long term. Another catalyst that will drive higher earnings and cash flow is Teledyne's M & A efforts, the analyst said.

Persons: Goldman Sachs, Noah Poponak, Goldman, Poponak, — CNBC's Michael Bloom Organizations: Teledyne Technologies, Teledyne, FLIR Systems

☆ These 'high quality compounders' are Bank of America's top picks ahead of second quarter earnings
▼ + stars: | 2023-07-15 | by ( Michael Bloom | ) www.cnbc.com time to read: +6 min

Analysts' at Bank of America have named a host of stocks that are poised to outperform heading into second earnings season. The bank said this week there are several "high quality" buying opportunities that aren't getting enough investor attention. CNBC Pro combed through the top Bank of America research to find analysts' favorite ideas as earnings releases ramp up. They include: Mondelez, SolarEdge , Rollins, Thomson Reuters and Broadcom. Bank of America recently initiated coverage of the stock with a buy rating, calling Rollins "a high-growth compounder through economic cycles."

Persons: SolarEdge, Rollins, Thomson, Jason Haas, Haas, BofA, Julien Dumoulin, Smith, Dumoulin, Heather Balsky, Balsky, Dirk Van de, MDLZ Organizations: Bank of America, CNBC, Thomson Reuters, Broadcom, Rollins, . Bank of America Locations: 2Q23, Europe, U.S

☆ Goldman Sachs says A.I. will 'super-charge' music creation and names 5 stocks to buy
▼ + stars: | 2023-07-05 | by ( Lucy Handley | ) www.cnbc.com time to read: +3 min

The music industry is set for a radical shift due in part to generative AI, according to Goldman Sachs , which described the new technology as providing "significant opportunities" for the sector. It named five buy-rated stocks to play the trend: Live Nation , Warner Music Group , French digital music company Believe , China's NetEase , and Universal Music Group . "Generative AI will super-charge music creation capabilities and improve productivity," according to Goldman's analysts in a June 28 note. The music industry is well set up to protect its intellectual property given that it is dominated by three large companies that own the majority of artists' catalogs, according to Goldman. Goldman chose Chinese internet company NetEase, which has a music streaming platform, for its use of AI in its music composition tools.

Persons: Goldman Sachs, NetEase, Drake, Goldman, WMG, UMG, CNBC's Michael Bloom Organizations: Warner Music Group, Universal Music Group, Companies, Spotify, Netflix Locations: Asia, Europe, Chinese

☆ FDA warns about safety risks of tailored weight-loss drugs
▼ + stars: | 2023-06-01 | by ( ) www.reuters.com time to read: +1 min

REUTERS/Lucas Jackson/File PhotoJune 1 (Reuters) - The U.S. Food and Drug Administration (FDA) warned about the safety risks of using compounded or custom-made versions of popular weight-loss drugs such as Wegovy and diabetes drug Ozempic. The FDA warned patients to refrain from using a compounded drug if an approved drug is available. Compounded drugs are created by combining, mixing, or altering ingredients to create a medication tailored to the needs of an individual patient. The agency said it does not review compounded versions of these drugs for safety, effectiveness, or quality, adding, it had received reports that compounders might be using salt forms of semaglutide, which are different active ingredients than those used in the approved drugs. The U.S. is expected to account for as much as 90% of weight-loss drug sales due to the number of potential patients and higher pricing than other countries, industry analysts and executives say.

Persons: Lucas Jackson, Novo, Mariam Sunny, Rashmi Organizations: REUTERS, U.S . Food, Drug Administration, Thomson Locations: New York, U.S, Bengaluru

Search resuls for: "compounders"

25 mentions found